(INGR) Ingredion - Overview
Stock: Starches, Sweeteners, Corn Oil, Gluten Feed, Gluten Meal
| Risk 5d forecast | |
|---|---|
| Volatility | 19.3% |
| Relative Tail Risk | -9.26% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.03 |
| Alpha | -23.20 |
| Character TTM | |
|---|---|
| Beta | 0.296 |
| Beta Downside | -0.232 |
| Drawdowns 3y | |
|---|---|
| Max DD | 29.95% |
| CAGR/Max DD | 0.26 |
EPS (Earnings per Share)
Revenue
Description: INGR Ingredion February 28, 2026
Ingredion Incorporated (NYSE: INGR) manufactures and sells a broad portfolio of corn-derived sweeteners, starches, nutrition ingredients, and biomaterial solutions for food, industrial, and specialty markets worldwide. Its operations are organized into three segments-Texture & Healthful Solutions, Food & Industrial Ingredients LATAM, and Food & Industrial Ingredients U.S./Canada-serving applications from processed foods and beverages to biodegradable plastics, textiles, and water-filtration systems.
In its most recent fiscal year (2025), Ingredion reported revenue of approximately **$6.2 billion**, a **4 % year-over-year increase**, and an adjusted earnings-per-share of **$1.48**. The company generated **$500 million** in free cash flow and maintained a **dividend of $0.30 per share**, yielding roughly **1.1 %**.
Key economic and sector drivers include: (1) sustained global demand for plant-based and clean-label ingredients, which is boosting sales of non-GMO sweeteners and specialty starches; (2) volatility in corn commodity prices-driven by weather patterns in the U.S. Midwest and shifting export policies-that directly impacts Ingredion’s cost structure; and (3) growing ESG focus, with increasing adoption of biodegradable plastics and other biomaterials that expand the market for Ingredion’s specialty industrial starches.
For a deeper quantitative view, you might explore Ingredion’s profile on ValueRay.
Headlines to watch out for
- Global food and beverage demand drives ingredient sales
- Commodity price fluctuations impact input costs
- Specialty ingredient innovation expands profit margins
- Regulatory changes affect corn and starch processing
- Currency exchange rates influence international revenue
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 729.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA -5.00 > 1.0 |
| NWC/Revenue: 30.32% < 20% (prev 27.91%; Δ 2.41% < -1%) |
| CFO/TA 0.12 > 3% & CFO 944.0m > Net Income 729.0m |
| Net Debt (760.0m) to EBITDA (1.23b): 0.62 < 3 |
| Current Ratio: 2.66 > 1.5 & < 3 |
| Outstanding Shares: last quarter (64.4m) vs 12m ago -3.16% < -2% |
| Gross Margin: 25.32% > 18% (prev 0.24%; Δ 2.51k % > 0.5%) |
| Asset Turnover: 94.11% > 50% (prev 99.81%; Δ -5.70% > 0%) |
| Interest Coverage Ratio: 27.32 > 6 (EBITDA TTM 1.23b / Interest Expense TTM 37.0m) |
Altman Z'' 6.41
| A: 0.28 (Total Current Assets 3.50b - Total Current Liabilities 1.32b) / Total Assets 7.90b |
| B: 0.71 (Retained Earnings 5.61b / Total Assets 7.90b) |
| C: 0.13 (EBIT TTM 1.01b / Avg Total Assets 7.67b) |
| D: 1.32 (Book Value of Equity 4.67b / Total Liabilities 3.53b) |
| Altman-Z'' Score: 6.41 = AAA |
Beneish M -3.04
| DSRI: 1.12 (Receivables 1.19b/1.09b, Revenue 7.22b/7.43b) |
| GMI: 0.95 (GM 25.32% / 24.10%) |
| AQI: 0.96 (AQ_t 0.24 / AQ_t-1 0.25) |
| SGI: 0.97 (Revenue 7.22b / 7.43b) |
| TATA: -0.03 (NI 729.0m - CFO 944.0m) / TA 7.90b) |
| Beneish M-Score: -3.04 (Cap -4..+1) = AA |
What is the price of INGR shares?
Over the past week, the price has changed by -2.23%, over one month by -7.29%, over three months by +0.70% and over the past year by -14.24%.
Is INGR a buy, sell or hold?
- StrongBuy: 1
- Buy: 1
- Hold: 5
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the INGR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 127 | 12.8% |
| Analysts Target Price | 127 | 12.8% |
INGR Fundamental Data Overview March 12, 2026
P/E Forward = 9.7466
P/S = 0.9927
P/B = 1.6495
P/EG = 1.3541
Revenue TTM = 7.22b USD
EBIT TTM = 1.01b USD
EBITDA TTM = 1.23b USD
Long Term Debt = 1.74b USD (from longTermDebt, last quarter)
Short Term Debt = 48.0m USD (from shortTermDebt, last quarter)
Debt = 1.79b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 760.0m USD (from netDebt column, last quarter)
Enterprise Value = 7.92b USD (7.17b + Debt 1.79b - CCE 1.03b)
Interest Coverage Ratio = 27.32 (Ebit TTM 1.01b / Interest Expense TTM 37.0m)
EV/FCF = 9.79x (Enterprise Value 7.92b / FCF TTM 809.0m)
FCF Yield = 10.21% (FCF TTM 809.0m / Enterprise Value 7.92b)
FCF Margin = 11.21% (FCF TTM 809.0m / Revenue TTM 7.22b)
Net Margin = 10.10% (Net Income TTM 729.0m / Revenue TTM 7.22b)
Gross Margin = 25.32% ((Revenue TTM 7.22b - Cost of Revenue TTM 5.39b) / Revenue TTM)
Gross Margin QoQ = 24.47% (prev 25.06%)
Tobins Q-Ratio = 1.00 (Enterprise Value 7.92b / Total Assets 7.90b)
Interest Expense / Debt = 0.50% (Interest Expense 9.00m / Debt 1.79b)
Taxrate = 19.32% (40.0m / 207.0m)
NOPAT = 815.6m (EBIT 1.01b * (1 - 19.32%))
Current Ratio = 2.66 (Total Current Assets 3.50b / Total Current Liabilities 1.32b)
Debt / Equity = 0.41 (Debt 1.79b / totalStockholderEquity, last quarter 4.34b)
Debt / EBITDA = 0.62 (Net Debt 760.0m / EBITDA 1.23b)
Debt / FCF = 0.94 (Net Debt 760.0m / FCF TTM 809.0m)
Total Stockholder Equity = 4.23b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.50% (Net Income 729.0m / Total Assets 7.90b)
RoE = 17.25% (Net Income TTM 729.0m / Total Stockholder Equity 4.23b)
RoCE = 16.94% (EBIT 1.01b / Capital Employed (Equity 4.23b + L.T.Debt 1.74b))
RoIC = 13.56% (NOPAT 815.6m / Invested Capital 6.01b)
WACC = 5.68% (E(7.17b)/V(8.96b) * Re(7.0%) + D(1.79b)/V(8.96b) * Rd(0.50%) * (1-Tc(0.19)))
Discount Rate = 7.0% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -1.52%
[DCF] Terminal Value 83.75% ; FCFF base≈939.4m ; Y1≈750.5m ; Y5≈507.3m
[DCF] Fair Price = 235.7 (EV 15.60b - Net Debt 760.0m = Equity 14.84b / Shares 62.9m; r=5.90% [WACC]; 5y FCF grow -24.05% → 2.90% )
EPS Correlation: 69.21 | EPS CAGR: 7.19% | SUE: -0.48 | # QB: 0
Revenue Correlation: -78.80 | Revenue CAGR: -1.95% | SUE: -0.77 | # QB: 0
EPS next Quarter (2026-06-30): EPS=2.95 | Chg7d=-0.010 | Chg30d=-0.014 | Revisions Net=-3 | Analysts=5
EPS current Year (2026-12-31): EPS=11.43 | Chg7d=+0.038 | Chg30d=-0.097 | Revisions Net=-1 | Growth EPS=+2.7% | Growth Revenue=+2.0%
EPS next Year (2027-12-31): EPS=12.03 | Chg7d=+0.178 | Chg30d=+0.132 | Revisions Net=+1 | Growth EPS=+5.2% | Growth Revenue=+3.0%
[Analyst] Revisions Ratio: -1.00 (0 Up / 3 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = -1.9% (Discount Rate 7.9% - Earnings Yield 9.8%)
[Growth] Growth Spread = +3.8% (Analyst 1.9% - Implied -1.9%)